noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Blizzard Entertainment Inc.

Black Ops 7 Season 04: Full Intel
City of Cathedral City, CA

Cathedral City Voters Encouraged to Cast Ballots in the June 2, 2026,[...]
Pennsylvania House Republican Caucus

Mehaffie’s Bills for Teachers, Healthcare Workers Pass Committees

Healthcare

Pappas Capital LLC

05/04/2026 | Press release | Archived content

Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a ...

News | 05. 04. 2026

Aktis Oncology

BOSTON, May 04, 2026 -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, today announced the initiation of a Phase 1b clinical trial of AKY-2519¹ in patients with metastatic castration-resistant prostate cancer (mCRPC). The mCRPC-dedicated Phase 1b trial is part of Aktis' clinical development strategy to develop AKY-2519 broadly in B7-H3 expressing tumors. Aktis plans to initiate a Phase 1b basket trial in lung, colorectal, and other high B7-H3 expressing solid tumors in the second half of 2026.

Pappas Capital LLC published this content on May 04, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 02, 2026 at 17:27 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format